Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of SEK 350 million before transaction costs.
The share issue was directed to a number of international and Swedish institutional investors on the basis of an accelerated bookbuilding process.
Vinge’s team consisted of Dain Hård Nevonen, Lorin Arabi and Elias Kröger.
